Epilepsy, a chronic neurological disorder characterized by recurrent, unprovoked seizures, poses significant challenges to healthcare professionals. Despite the availability of numerous antiepileptic drugs (AEDs), about one-third of patients continue to experience uncontrolled seizures. This article aims to provide an update on the latest advancements in epilepsy management.
The last decade has seen the introduction of several new-generation AEDs. These drugs, such as perampanel and brivaracetam, have demonstrated improved efficacy and tolerability. They act on novel targets, thus providing additional therapeutic options for patients with drug-resistant epilepsy. However, their long-term safety profiles remain to be fully established.
Neuromodulation therapies, such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Responsive Neurostimulation (RNS), have emerged as effective adjunctive treatments for drug-resistant epilepsy. These therapies modulate neuronal activity, thereby reducing seizure frequency and severity. While invasive, they offer substantial benefits for patients who are not surgical candidates or have failed epilepsy surgery.
Advances in genetic testing have revolutionized the diagnostic approach to epilepsy. By identifying the genetic basis of certain epilepsy syndromes, healthcare professionals can provide more personalized treatment plans. These advancements also hold promise for the development of targeted therapies.
Telemedicine has emerged as a vital tool in epilepsy management, particularly amidst the COVID-19 pandemic. It allows for remote patient monitoring, reducing the need for hospital visits, and facilitating timely intervention. Moreover, it enables wider access to specialized epilepsy care, especially for patients in remote areas.
Advancements in epilepsy management are transforming the landscape of patient care. While challenges remain, these innovations offer hope for improved seizure control and quality of life for patients with epilepsy. Healthcare professionals must stay abreast of these developments to provide optimal patient care.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
TULSA Is Effective in Long-Term Prostate Cancer Control.
3.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
4.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
5.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
3.
Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship
4.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation